Free Trial
NASDAQ:ARTV

Artiva Biotherapeutics Q1 2025 Earnings Report

Artiva Biotherapeutics logo
$1.60 -0.01 (-0.62%)
Closing price 06/25/2025 04:00 PM Eastern
Extended Trading
$1.64 +0.03 (+2.19%)
As of 06/25/2025 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artiva Biotherapeutics EPS Results

Actual EPS
-$0.83
Consensus EPS
-$0.68
Beat/Miss
Missed by -$0.15
One Year Ago EPS
N/A

Artiva Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Artiva Biotherapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Artiva Biotherapeutics' Q2 2025 earnings is scheduled for Thursday, August 7, 2025

Artiva Biotherapeutics Earnings Headlines

Artiva Biotherapeutics Approves Equity Plan Amendment
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
ARTV - Artiva Biotherapeutics Inc Key Metrics - Morningstar
See More Artiva Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Artiva Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artiva Biotherapeutics and other key companies, straight to your email.

About Artiva Biotherapeutics

Artiva Biotherapeutics (NASDAQ:ARTV), a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

View Artiva Biotherapeutics Profile

More Earnings Resources from MarketBeat